We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GAP:NYSEGap, Inc. (The) Analysis

Data as of 2026-04-05 - not real-time

$24.61

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Gap reported a modest 2% increase in net sales and a 3% rise in comparable sales for Q4 FY2025, delivering an operating margin of 7.3% that beat its outlook and generating $1.3 billion of operating cash flow, while authorizing a $1 billion share‑repurchase program. The stock trades at $24.61, which is above the DCF‑derived fair value of $20.88, implying roughly a 24% valuation premium, yet analysts’ consensus target of $31 suggests an additional upside of about 25%. Technically, the price sits just above the 20‑day SMA (24.04) and the MACD histogram is positive, indicating a bullish tilt, while the RSI of 46.8 points to a neutral momentum environment. Valuation metrics such as a trailing PE of 11.6 and forward PE of 9.4 position Gap as a value‑oriented play, though the high beta (~1.2) and 30‑day volatility of 57% underscore price sensitivity. The dividend yield of 2.84% with a 31% payout ratio appears sustainable given strong free cash flow and a solid ROE of 23%. However, a debt‑to‑equity ratio of 148% and decreasing volume signal heightened financial and liquidity risk. Overall, the stock offers a blend of modest growth, attractive yield, and upside potential, but investors should weigh the elevated volatility and leverage before committing.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Earnings beat and strong cash flow
  • Neutral technical stance near resistance
  • High short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst target price implying ~25% upside
  • Sustainable dividend yield
  • Share‑repurchase program supporting price

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Diversified brand portfolio with steady earnings
  • Attractive valuation relative to peers
  • Long‑term cash generation despite leverage

Key Metrics & Analysis

Financial Health

Revenue Growth2.10%
Profit Margin5.31%
P/E Ratio11.6
ROE23.10%
ROA5.62%
Debt/Equity147.62
P/B Ratio2.4
Op. Cash Flow$1.3B
Free Cash Flow$701.2M

Technical Analysis

TrendNeutral
RSI46.8
Support$22.03
Resistance$25.84
MA 20$24.04
MA 50$26.26
MA 200$23.95
MACDBullish
VolumeDecreasing
Fear & Greed Index78.8

Valuation

Fair Value$20.88
Target Price$30.65
Upside/Downside24.55%
GradeFair
TypeBlend
Dividend Yield2.84%

Risk Assessment

Beta1.17
Volatility57.45%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.